Robotic cats, dogs and therapy robots for aged care homes, dementia units and families across Australia. · Call 0485 939 966

Do robotic pets reduce antipsychotic use?

What robotic pet trials show on antipsychotic and other psychotropic medicine use in dementia care, and how the QI Program, mandatory since 2019, tracks it.

Do robotic pets reduce antipsychotic use?

No large trial has shown that robotic pets reduce antipsychotic use in people living with dementia. One small American study of 61 people reported lower use of psychoactive medicines with PARO, but its behaviour medication result was not significant once the analysis adjusted for demographics. The Queensland PARO trial of 415 residents reported engagement, mood and agitation, and no medication result. A robotic pet can still be a documented non-drug strategy, and any change to medicines is a decision for the prescriber.

Why antipsychotic use is tracked in Australian aged care

Every Australian Government funded residential aged care home has had to take part in the National Aged Care Quality Indicator Program (QI Program) since 1 July 2019. Homes report on 14 quality indicators every three months, and medication management is one of them. For the antipsychotics measure, staff review each resident’s medication chart over a seven-day period each quarter and report the share who received an antipsychotic, with residents who have a medically diagnosed psychosis counted separately. The QI Program Manual explains why: use of certain medication classes, such as antipsychotics, has been linked to poor health outcomes.

Antipsychotics also fall under the restrictive practice rules when they are used mainly to change behaviour. The Aged Care Quality and Safety Commission defines chemical restraint as a practice or intervention involving medication for the primary purpose of influencing behaviour. Section 18 of the Aged Care Act 2024 requires the rules to allow a restrictive practice only as a last resort to prevent harm, with alternative strategies used first where possible and documented.

Which robotic pet studies measured medication use

Study Setting and size What it reported on medication
Petersen and colleagues, Journal of Alzheimer’s Disease, 2017 61 people in five secure dementia units in the United States, PARO three times a week for 12 weeks Pain and behaviour medication use fell in the PARO group on the unadjusted comparison. After adjusting for demographics, the group effect was not significant for behaviour or sleep medication
Moyle and colleagues, JAMDA, 2017 415 residents in 28 Queensland facilities, PARO against a plush toy and usual care for 10 weeks Medication was not among the primary outcomes, which were engagement, mood and agitation
Mervin and colleagues, JAMDA, 2018 Cost analysis nested in the same Queensland trial Framed around agitation and medication use. The published abstract reports costs and no significant difference in agitation between groups, and gives no medication result
Fan and colleagues, Journal of Medical Internet Research, 2025 Pooled review of 15 randomised trials Reports agitation, anxiety, cognition, depression and quality of life. The abstract reports no medication outcome

The Petersen paper, open access on PubMed Central, is the only study in this table with a medication result. Its authors caution against generalising beyond their sample. They also noted that health providers were reluctant to reduce antidepressants even when depression scores improved.

What the larger trials found and did not measure

In the Griffith University trial, video coding showed PARO residents were less agitated and showed more pleasure than residents in usual care. The staff-completed Cohen-Mansfield agitation scores did not separate the groups. A later analysis of the PARO arm found residents with severe agitation at the start responded poorly, and the authors recommended PARO for low to moderate agitation only.

That matters for medication questions. A trial that did not measure medication cannot show a medication effect, and an effect on agitation during sessions does not show that a resident’s need for an antipsychotic has changed. The research summary covers the agitation and engagement findings in more detail.

Why a non-drug strategy matters even without a medication effect

The national Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard (2024) sets the expectations:

  • Quality statement 4: non-medication strategies are used first-line and as the mainstay of care for behaviours of concern, are tailored to the person, and are documented and communicated. They should continue even if a psychotropic medicine is trialled, and medicines should not be used on their own.
  • Quality statement 6: avoid prescribing psychotropic medicines for behaviours of concern. Before prescribing, a reasonable and systematic trial of non-medication strategies should have taken place and been found ineffective or inadequate.
  • Quality statement 7: a person’s response to psychotropic medicines is monitored and reviewed regularly, with dose reduction or stopping considered at each review.

Dementia Support Australia notes that simulated pets have often been used as an alternative to medication for behaviours such as agitation and loneliness, and that they do not suit everyone. Read together, a robotic pet is worth recording as one tried strategy among several, whether or not it changes a prescription. How to write it into the behaviour support plan is covered in robotic pets and the Quality Standards.

Bringing the record to a medication review

Under quality statement 7, a review should use objective information, such as behaviour monitoring and reports from family and support workers. Notes from a robotic pet trial can feed into that. Useful items:

  • Dates, times and length of each session, and who offered the pet.
  • What happened: settled, engaged, ignored it, became distressed.
  • Behaviour charts for the weeks before and during the trial.
  • Any PRN doses given around the sessions, with the reason recorded.
  • Family observations from visits.

The clinical care standard lists the Residential Medication Management Review as a Medicare-funded medication review for people in eligible Australian Government funded aged care homes. Since 1 July 2024, the Government has also funded on-site pharmacists in residential aged care, at one pharmacist per 250 beds, in 50-bed increments. Participation is voluntary, so ask whether your home has one.

What to say, and not say, to families and prescribers

Say Avoid
We are trying a robotic pet as one of several non-drug strategies and will record how Dad responds This should let us take him off his tablets
Some studies found less agitation during sessions; it does not help everyone Research proves robotic pets cut antipsychotic use
Any change to medicine is the doctor’s decision at a review We will stop the medication if the pet works
We will bring our notes to the next medication review The pet replaces the behaviour support plan

The limits of robotic pets page sets out other things to avoid promising.

What to do next

Start with a short, recorded trial for residents who have shown interest, using the introduction checklist. If your clinical team wants a set for that trial, request quotes for a non-drug strategy trial.

Request quotes

Frequently asked questions

Can a robotic pet replace antipsychotic medication?

There is no good evidence that it can. Whether to reduce or stop an antipsychotic is a clinical decision made at a medication review. A robotic pet can sit in the care plan as one non-drug strategy, used alongside others and alongside any medicine the doctor prescribes.

Did the Queensland PARO trial measure medication use?

Its main paper measured engagement, mood and agitation. A cost analysis from the same trial was framed around agitation and medication, but its abstract reports costs and agitation only. So the trial does not give a medication answer either way.

Does a robotic pet count as an alternative strategy before chemical restraint?

It can be listed as one, if it is actually offered, suits the person and the result is written down. The law asks for alternatives to be tried where possible and documented before any restrictive practice. A single strategy on paper that was never tried does not meet that test.

What is the antipsychotic quality indicator?

It is part of the medication management indicator in the national QI Program. Each quarter, homes check every resident's medication chart over seven days and report the percentage who received an antipsychotic. Residents with a diagnosed psychosis are also reported separately.

Who decides whether to reduce a resident's medication?

The prescriber, usually the resident's GP, together with the resident or their decision maker. A pharmacist review can recommend changes. Care staff and families contribute observations, including records from a robotic pet trial, but they do not change doses themselves.

0485 939 966